Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Investor Presentation (August 2021)
36 slides from Definium Therapeutics's investor presentation, Aug 13, 2021
Slide 1: MindMed: Discover. Develop. Deploy.
MindMed Discover. Develop. Deploy. www.mindmed.co Psychedelic Inspired Medicines August 2021 MMED MNMD MMQ NASDAQ NEO DE MindMed
Slide 2: Disclaimer
Disclaimer Corporate Presentation | August 2021 MindMed 1 This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers
Slide 3: Leadership: A Combination of Drug Developers & Technologists
Leadership: A Combination of Drug Developers & Technologists Corporate Presentation | August 2021 MindMed 2 Daniel Karlin, MD, MA Bradford Cross Miri Halperin Wernli, PhD Robert Barrow Chief Medical Officer Chief Technology Officer Executive President & Board Director Chief Executive Officer Dan pre
Slide 4: Therapeutic Area Selection to Address Massive Unmet Needs
Corporate Presentation | August 2021 MindMed 3 8 Tactical Capital Allocation to Advance Strategic Success Therapeutic Area Selection to Address Massive Unmet Needs Targeting Major Psychiatric Disorders Increasing Burden over Time Anxiety Disorders Major Depressive Disorder Pain Disorders OUD TRD CH
Slide 5: MindMed is a Mental Health Company
MindMed is a Mental Health Company Corporate Presentation | August 2021 MindMed Rigorously Applied Drug Development Principles to a Novel Drug Class 4 Novel Mechanisms of Action Strong potential efficacy signals Bridges psychotherapy and pharmacology Long history of well - tolerated use in clinical
Slide 6: Advancing Therapeutic Improvements across the Full Life Cycle
Corporate Presentation | August 2021 MindMed 5 Deploy Innovative approaches to tech, payers, and providers to facilitate scalability and accessibility leveraging the current treatment landscape Develop Consistently adhere to rigorous development pathways to enable worldwide market access Discover NC
Slide 7: Multiple Generations of Potential Drug Candidates from Classic Psychedelics
Corporate Presentation | August 2021 MindMed 6 Multiple Generations of Potential Drug Candidates derived from Classic Psychedelics Psychedelic - Inspired Medicine Opportunity Illustrative purposes only Evidence of potential for positive clinical benefit • Novel tryptamines Novel phenethylamines Non
Slide 8: Strong IP & Strategic Competitive Moats
Advancing the Field with Strong IP & Strategic Competitive Moats Corporate Presentation | August 2021 MindMed 7 Protecting Innovation and Market Potential Our Patent Positions are Extensive and Diverse 45+ patent applications filed 45+ molecules covered 10+ patent applications covering LSD 3+ patent
Slide 9: Science & Background
Corporate Presentation | August 2021 MindMed 8 Science & Background The Case for Psychedelic - Inspired Therapies
Slide 10: A Strong Case for Psychedelic Research
Corporate Presentation | August 2021 MindMed A Strong Case for Psychedelic Research Psychedelic Inspired Medicines: A New Treatment Paradigm 9 Global Brain Connectivity Enrichment of 5 - HT2A Expression 2.0 1.5 1.0 0.5 0.0 Placebo Increased single neuron excitability Layer V pyramidal neuron Psyched
Slide 11: Strong Historical Third Party Clinical Research on LSD
This slide contains market and industry data that has been obtained from third party sources. Please refer to “Market and Ind ust ry Data” on Slide 2 10 Corporate Presentation | August 2021 MindMed Strong Historical Third Party Clinical Research Presents Opportunity for Accelerated Development LSD |
Slide 12: Substantial Body of Evidence Supports Efficient Development
Corporate Presentation | August 2021 MindMed 1 1 Substantial Body of Evidence Supports Efficient Development LSD | Stands Out among the Psychedelic Drug Class Opportunities LSD: Overlooked & Undervalued Single administration with rapid and sustained action • Robust clinical response in a wide range
Slide 13: Applications Beyond Psychiatry: LSD in Pain
Corporate Presentation | May 2021 MindMed 29 Corporate Presentation | August 2021 MindMed 12 Applications Beyond Psychiatry LSD | Emerging Evidence in Pain & Somatic Disorders Low Dose LSD Increases Pain Tolerance and Decreases Perceived Pain Source: [14] Source: [13] Time after administration (hour
Slide 14: 18-MC: Non-hallucinogenic Congener of Ibogaine
13 Corporate Presentation | August 2021 MindMed Non - hallucinogenic, non - cardiotoxic congener of ibogaine 18 - MC | Psychedelic - Inspired NCE: 18 - MC 18 - MC regulates dopamine While potentially life - saving, current therapies for OUD primarily work by engaging opioid receptors Dopamine - Low
Slide 15: 18-MC Reduces Morphine and Cocaine Self-Administration
14 Corporate Presentation | August 2021 MindMed (mg/kg i.p.) 120 100 80 60 40 20 0 10 20 30 40 Percentage of Baseline 18 - MC Water Cocaine (mg/kg i.p.) 120 100 80 60 40 20 0 10 20 30 40 Percentage of Baseline 18 - MC Water Morphine Non - hallucinogenic, non - cardiotoxic congener of ibogaine 18 - M
Slide 16: Develop & Discover
Our Division For Concept Testing of NCEs and Classic Psychedelics Corporate Presentation | August 2021 MindMed 15 Develop & Discover
Slide 17: Our Robust and Diverse Development Pipeline
Corporate Presentation | August 2021 MindMed *Study in planning Note: Does not include Phase 1 studies being conducted at UHB with a primary objective related to mechanism of action or cros s - m olecule comparative PK and/or PD studies Pipeline Diversification Offers Access To Full Potential Of Psy
Slide 18: Diversified Strategy across Development Franchises
Corporate Presentation | August 2021 MindMed 1 7 Diversified Strategy across Development Franchises LSD Clinical Development Program Randomized, double - blind, placebo - controlled, 2 - period crossover n = 40 patients ONGOING Randomized, double - blind, active - placebo - controlled, parallel desi
Slide 19: MMED005: Phase 2 Study of 18-MC in Opioid Withdrawal
Enrolling 96 patients at multiple centers in the US Expected Start: Early 2022 Expected Readout: Mid 2023 Study MMED005: Phase 2 Proof - of - Concept Study of 18 - MC in Opioid Withdrawal 18 - MC for Substance Use Disorders Endpoints Design DSM - 5 OUD Patients undergoing opioid withdrawal SOWS - Go
Slide 20: Collaborations & Data Acquisition Enable Rapid Path to Development
Corporate Presentation | August 2021 MindMed 19 Collaborations & Data Acquisition enable Rapid Path to Development With Significantly Less Risk Collaborative Approach for Accelerating Value Completed Phase 1 Ongoing Phase 1 Ongoing Phase 2 Planned Phase 1 LSD for Anxiety Disorders LSD for Cluster He
Slide 21: Robust Pipeline Driven by Collaborative Arrangements
Robust pipeline driven by collaborative arrangements R&D Pipeline Corporate Presentation | August 2021 MindMed 20 IP: intellectual property, R&D: research and development • • • Exclusive rights to completed and ongoing clinical study data Execution of Phase 1/2 studies on known and novel psychedelic
Slide 22: Near-Term and Intermediate Value Drivers
Corporate Presentation | August 2021 MindMed 21 Near - Term and Intermediate Value Drivers DRUG CANDIDATE INDICATION LATE 2021 2022 MILESTONE ADDICTION FRANCHISE 18 - MC — Project Layla Opioid Use Disorder Complete Phase 1 SAD/MAD study Launch Phase 2a proof - of - concept study PSYCHIATRY FRANCHISE
Slide 23: Deploy
15 Corporate Presentation | August 2021 MindMed 22 Deploy Our Division To Enable Scalability & Accessibility of Our Drug Programs
Slide 24: Scalable Delivery Platform to Leverage Current Ecosystem
Scalable Delivery Platform to Enable Leveraging of Current Ecosystem Donating $5 million over a 5 - year period Establish the gold standard of training programs to educate healthcare providers and psychedelic researchers Use digital medicine technology to promote outcomes and engagement at all phase
Slide 25: Scalable Delivery Platform: Digital Medicine Components
Scalable Delivery Platform to Enable Adoption Leveraging the Current Ecosystem MindMed 24 Corporate Presentation | August 2021 Note: application images are for illustrative purposes only. Digital Medicine: Multiple components of the MindMed platform Early Engagement & Education Treatment Session Lon
Slide 26: Psychedelics Driving Progressive Care and Payment Models
Corporate Presentation | August 2021 MindMed 25 Psychedelics Driving Progressive Care and Payment Models Complementary Digital Medicine Approach for Improved Mental Health Outcomes Digital Measurement enables value - based clinical models Driving engagement through friction reducing patient technolo
Slide 27: Digital Measures, Diagnostics & Therapeutics to Enable Commercial Viability
2 Digital Measures, Diagnostics & Therapeutics to Enable Commercial Viability Corporate Presentation | August 2021 MindMed 26 Building Toward Novel Care and Reimbursement Models Build measurement, diagnostic and therapeutic models using real world data 1 Validate measures, diagnostics, and intervent
Slide 28: Developing Platform to Utilize all Relevant Data Types
Developing Platform to Utilize all Relevant Data Types MindMed Machine Learning Measurements Audio* Text Behavioral* Genomic Biological Mobile* Smartwatch* Partner Integrations Diagnostics Therapeutics Anxiety Addiction PTSD Pain ADHD Applications Data Models MindMed Corporate Presentation | August
Slide 29: Digital Medicine Development Pipeline
Corporate Presentation | August 2021 MindMed 28 Planned Late 2021 – Progress to clinical data collection Substance Use Disorders Substance Use Detection PAIN NEUROLOGY ADDICTION PSYCHIATRY PRE - CLINICAL PHASE 1 PHASE 2A PHASE 2B PHASE 3 COMMERCIAL LAUNCH In development - Concept development Anxiety
Slide 30: Corporate Information
Corporate Presentation | August 2021 MindMed 29 Corporate Information
Slide 31: Share Ownership and Capitalization
65,468,007 13.8% 74.2% 7.0% 100% Executive Team/Directors/Insiders Share Ownership as of August 1, 2021 Non - insider shares Equity Incentive Plan (Issued) Total (Fully diluted) 351,330,630 33,082,892 473,269,160 $204 million Raised since inception including warrants $160 million Cash position as of
Slide 32: Scientific Advisors: World Class Expert Support
Scientific Advisors: World Class Expert Support Corporate Presentation | August 2021 MindMed 31 Robert Malenka, MD, PhD John Blacker, PhD Jed Rose, PhD Kenneth Alper, MD Maurizio Fava, MD Peter Bergethon, MD Matthew Johnson, PhD Stanley Glick, PhD Sarah McCallum, PhD Chairman of the Scientific Advis
Slide 33: Board of Directors
Board of Directors Corporate Presentation | August 2021 MindMed 32 Miri Halperin Wernli, PhD Perry Dellelce Bruce Linton Stephen Hurst, JD Brigid Makes Executive President, Director Chairman of the Board of Directors Director, Chair of Compensation, Governance and Nominating Committee Co - Founder a
Slide 34: Public Perception of Psychedelics Has Changed
Public Perception of Psychedelics Has Changed Corporate Presentation | August 2021 MindMed 33 “Psychedelics - Drug Startup Raises $24 Million Ahead of IPO.” February 27, 2020 “This could save lives, cure depression, help alcoholism, get people off opioids — why wouldn’t I want to be invested?” - Kev
Slide 35: MindMed
Corporate Presentation | August 2021 MindMed 34 MindMed
Slide 36: Sources
Corporate Presentation | August 2021 MindMed 35 Sources Mental Health By the Numbers | NAMI: National Alliance on Mental Illness. (2019). NAMI. https://www.nami.org/mhstats#:%7E:tex t=2 0.6%25%20of%20U.S.%20adults%20experienced,represents%201%20in%2020%20adult Bandelow, Borwin, and Sophie Michaelis.
Mind Medicine (MindMed) — Investor Presentation (August 2021) on 6ix